Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of tropomyosin receptor kinase inhibitors in adult and pediatric patients with neurotrophic receptor tyrosine kinase fusion-
暂无分享,去创建一个
Y. Kodera | E. Oki | E. Baba | K. Tsuchihara | M. Sanada | H. Kajiyama | M. Ikeda | T. Hishiki | S. Ohga | H. Kenmotsu | T. Koyama | T. Yoshino | K. Akagi | A. Igarashi | H. Nishihara | K. Komine | M. Miyachi | I. Sekine | W. Okamoto | Y. Naito | T. Takano | Y. Yatabe | S. Kadowaki | K. Terashima | S. Mishima | Akira Hirasawa | Hiroyuki Nishiyama | K. Tao | N. Hayashi | Osamu Maeda | M. Kato | Shigeru Ono
[1] L. Weiss,et al. NTRK Fusions and Trk Proteins: What are They and How to Test for Them. , 2021, Human pathology.
[2] Wei Zhang,et al. A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors , 2020, Therapeutic advances in medical oncology.
[3] S. Bielack,et al. Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies. , 2020, European journal of cancer.
[4] Jessica L. Davis,et al. Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST) , 2020, Modern Pathology.
[5] A. Gaumann,et al. Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification , 2020, Zeitschrift für Gastroenterologie.
[6] Y. Kodera,et al. JSCO/ESMO/ASCO/JSMO/TOS: International expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] M. Ladanyi,et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. , 2020, The Lancet. Oncology.
[8] A. Drilon,et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.
[9] M. Ladanyi,et al. Identifying patients with NTRK fusion cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] C. Zerbini,et al. PPM11 TUMOUR-SPECIFIC RANDOMIZED CONTROLLED TRIALS IN RARE ONCOGENE-DRIVEN CANCERS: ASKING FOR THE IMPOSSIBLE? , 2019, Value in Health.
[11] Arun K. Ramani,et al. Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas , 2019, Nature Communications.
[12] M. Ladanyi,et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls , 2019, Modern Pathology.
[13] A. Zehir,et al. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy , 2019, The Journal of molecular diagnostics : JMD.
[14] J. Hechtman,et al. Detection of NTRK Fusions: Merits and Limitations of Current Diagnostic Platforms. , 2019, Cancer research.
[15] F. Penault-Llorca,et al. Testing algorithm for identification of patients with TRK fusion cancer , 2019, Journal of Clinical Pathology.
[16] Akihiko Yoshida,et al. Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study , 2019, Cancer science.
[17] Jessica L. Davis,et al. TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] J. Sicklick,et al. Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric Malignancies: Implications for NTRK-Targeted Therapeutics. , 2018, JCO precision oncology.
[19] A. Drilon,et al. NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.
[20] A. Drilon,et al. Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] J. Krauss,et al. Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] Jessica L. Davis,et al. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas , 2018, Cancer.
[23] J. Swensen,et al. Molecular characterization of cancers with NTRK gene fusions , 2018, Modern Pathology.
[24] A. Drilon,et al. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. , 2018, Cancer discovery.
[25] C. Fletcher,et al. Evaluation of pan‐TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis‐like neural tumour and histological mimics , 2018, Histopathology.
[26] Jessica L. Davis,et al. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors , 2018, The American journal of surgical pathology.
[27] M. Gessler,et al. ETV6–NTRK3 in congenital mesoblastic nephroma: A report of the SIOP/GPOH nephroblastoma study , 2018, Pediatric blood & cancer.
[28] Funda Meric-Bernstam,et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.
[29] Kenneth L. Jones,et al. Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[30] M. Ladanyi,et al. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions , 2017, The American journal of surgical pathology.
[31] A. Iafrate,et al. Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion. , 2017, JCO precision oncology.
[32] M. Stevens,et al. Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience. , 2016, European journal of cancer.
[33] R. Shoemaker,et al. Detecting Gene Rearrangements in Patient Populations Through a 2-Step Diagnostic Test Comprised of Rapid IHC Enrichment Followed by Sensitive Next-Generation Sequencing , 2016, Applied immunohistochemistry & molecular morphology : AIMM.
[34] A. D. Dei Tos,et al. Transcriptome sequencing identifies ETV6–NTRK3 as a gene fusion involved in GIST , 2016, The Journal of pathology.
[35] A. Sartore-Bianchi,et al. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types , 2016, ESMO Open.
[36] T. Vaněček,et al. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion , 2016, The American journal of surgical pathology.
[37] Gang Li,et al. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. , 2015, Cancer discovery.
[38] A. Vincent-Salomon,et al. Secretory Breast Carcinoma: A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion , 2015, The American journal of surgical pathology.
[39] Amar Gajjar,et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma , 2014, Nature Genetics.
[40] D. Deschler,et al. Mammary analogue secretory carcinoma: Update on a new diagnosis of salivary gland malignancy , 2014, The Laryngoscope.
[41] J. Bishop,et al. Utility of mammaglobin immunohistochemistry as a proxy marker for the ETV6-NTRK3 translocation in the diagnosis of salivary mammary analogue secretory carcinoma. , 2013, Human pathology.
[42] B. Perez-Ordonez,et al. Mammary Analogue Secretory Carcinoma of Salivary Glands, Containing the ETV6-NTRK3 Fusion Gene: A Hitherto Undescribed Salivary Gland Tumor Entity , 2010, The American journal of surgical pathology.
[43] A. Gulino,et al. Alternative TrkAIII splicing: a potential regulated tumor-promoting switch and therapeutic target in neuroblastoma. , 2005, Future oncology.
[44] P. Sorensen,et al. A fluorescence in situ hybridization study of ETV6‐NTRK3 fusion gene in secretory breast carcinoma , 2004, Genes, chromosomes & cancer.
[45] P. Sorensen,et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. , 2002, Cancer cell.
[46] M. Caligiuri,et al. Identification and Characterization of an Activating TrkA Deletion Mutation in Acute Myeloid Leukemia , 2022 .
[47] P. Sorensen,et al. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. , 2000, The American journal of surgical pathology.
[48] J. Fletcher,et al. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma. , 1998, The American journal of pathology.
[49] P. Sorensen,et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma , 1998, Nature Genetics.
[50] A. Cantor,et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. , 1993, The New England journal of medicine.
[51] D. Kaplan,et al. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. , 1991, Science.
[52] M. Barbacid,et al. The trk proto-oncogene encodes a receptor for nerve growth factor , 1991, Cell.
[53] M. Barbacid,et al. Oncogenes in solid human tumours , 1982, Nature.
[54] R. Doebele,et al. TRKing down an old oncogene in a new era of targeted therapy. , 2015, Cancer discovery.
[55] H. Abel,et al. Translocation Detection Using Next-Generation Sequencing , 2015 .
[56] P. Argani,et al. Detection of the ETV6-NTRK3 Chimeric RNA of Infantile Fibrosarcoma/Cellular Congenital Mesoblastic Nephroma in Paraffin-Embedded Tissue: Application to Challenging Pediatric Renal Stromal Tumors , 2000, Modern Pathology.